Pharmaceuticals Search Engine [selected websites]

Blog Archive

Tuesday, February 19, 2008

IPSOGEN, Genomic Grade to improve Breast Cancer diagnosis & treatment decision

Marseille, France, January 28, 2007 – IPSOGEN SAS, a leading molecular diagnostic company based in France and Connecticut, USA announced today the signature of a license agreement with Université Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™...The Genomic Grade™ represents the common core feature of the main breast cancer prognostic genomic signatures published worldwide, as shown by a meta-analysis presented by Pr. Piccart at the St. Gallen Breast Cancer conference in March 2007. Importantly, the Genomic Grade™ can be measured by both DNA microarray and multiplex PCR technologies, as presented at the 2007 meeting of the American Society of Clinical Oncology... [PDF] IPSOGEN's Press Release-